Ap­petite for gene ther­a­pies gains mo­men­tum, as Bio­gen plans $800M buy­out of Night­star Ther­a­peu­tics

An­oth­er day, an­oth­er gene ther­a­py deal. The lure of the one-shot cure for rare eye dis­eases — a niche pock­et with­in the broad­er ar­se­nal of gene ther­a­pies — is en vogue, with Roche’s $4.3 bil­lion buy­out of Lux­tur­na mak­er Spark Ther­a­peu­tics $ONCE and J&J fork­ing out up to $440 mil­lion to col­lect the rights to MeiraGTx’s slate of one-shot oph­thal­mo­log­i­cal ther­a­pies this year. On Mon­day, Bio­gen joined the fes­tiv­i­ties with its agree­ment to ac­quire Lon­don’s Night­star Ther­a­peu­tics $NITE for rough­ly $800 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER